Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: Data from the EFECT trial

Breast Cancer Research and Treatment

Volumn 117, Issue 1, 2009, Pages 69-75

  Mauriac, Louis ^a   Romieu, Gilles ^b   Bines, José ^c  

^a INSTITUT BERGONIÉ   (France)

^b CENTRE VAL D AURELLE   (France)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Advanced breast cancer; Aromatase inhibitors; Clinical trial; Exemestane; Fulvestrant; Visceral metastases

Indexed keywords

EXEMESTANE; FULVESTRANT; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER METASTASIS; LOADING DRUG DOSE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; VISCERA;

EID: 69049097227     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0141-z     Document Type: Article

References (15)

1. EF Solomayer IJ Diel GC Meyberg C Gollan G Bastert 2000 Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis Breast Cancer Res Treat 59 271 278 10.1023/A:1006308619659
2. National Cancer Institute PDQ Statement (2007) Breast cancer (PDQ): treatment. Stage IIIB, inoperable IIIC, IV, recurrent, and metastatic breast cancer. Available via http://www.nci.nih.gov/cancertopics/pdq/treatment/breast/ HealthProfessional/page8. Accessed 8 May 2007
3. National Comprehensive Cancer Network (2007) NCCN Clinical practice guidelines in oncology, Version I: Breast cancer. Available via http://www.nccn.org. Accessed 30 Mar 2007
4. M Kaufmann E Bajetta LY Dirix et al. 2000 Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group J Clin Oncol 18 1399 1411
5. A Howell JF Robertson I Vergote 2003 A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases Breast Cancer Res Treat 82 215 222 10.1023/B:BREA.0000004375.17920.0b
6. L Mauriac JE Pippen J Quaresma Albano SZ Gertler CK Osborne 2003 Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials Eur J Cancer 39 1228 1233 10.1016/S0959-8049(03)00199-0
7. JN Ingle VJ Suman KM Rowland et al. 2006 Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032 J Clin Oncol 24 1052 1056 10.1200/JCO.2005.04.1053
8. L Perey R Paridaens H Hawle et al. 2007 Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00) Ann Oncol 18 64 69 10.1093/annonc/mdl341
9. C Gennatas V Michalaki E Carvounis et al. 2006 Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO) Tumori 92 13 17
10. N Steele J Zekri R Coleman et al. 2006 Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure Breast 15 430 436 10.1016/j.breast.2005.08.032
11. P Carlini A Michelotti G Ferreti et al. 2007 Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients Cancer Invest 25 102 105 10.1080/07357900701224789
12. S Chia W Gradishar L Mauriac et al. 2008 A double-blind, randomized, placebo-controlled trial of fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy in post-menopausal women with hormone receptor-positive advanced breast cancer: results from EFECT J Clin Oncol 26 1664 1670 10.1200/JCO.2007.13.5822
13. P Therasse SG Arbuck EA Eisenhauer et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 3 205 216 10.1093/jnci/92.3.205
14. GG Steger M Gips SD Simon et al. 2005 Fulvestrant ('Faslodex'): clinical experience from the compassionate use programme Cancer Treat Rev 31 Suppl 2 S10 S16 10.1016/j.ctrv.2005.08.009
15. P Neven R Paridaens G Pelgrims et al. 2008 Fulvestrant ('Faslodex') in advanced breast cancer: clinical experience from a Belgian cooperative study Breast Cancer Res Treat 109 59 65 10.1007/s10549-007-9628-2